Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article discusses research on NAD+ precursor supplements. It is informational only and is not medical advice. Consult a qualified healthcare professional before starting, stopping, or changing any supplement regimen, especially if you take medications or have a chronic condition.

TL;DR

• NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two NAD+ precursor supplements with the most human data. Both raise circulating NAD+ at typical doses; neither has definitive clinical outcome evidence in humans.
• Typical doses studied: NMN 250-1000 mg/day, NR 250-500 mg/day. The dose-response curve flattens above roughly 500 mg/day in available trials of either compound.
• Cost in 2026 is roughly comparable per gram once you control for purity. NR has more concentrated brand consolidation around ChromaDex’s Tru Niagen; NMN is fragmented across many producers, with quality and price both more variable.
• Safety profiles look clean at studied doses over 12-week to 12-month trial durations. Long-term safety beyond 24 months remains preliminary in humans for either compound.
• US regulatory status differs sharply: NR is an accepted dietary supplement; NMN was reclassified by the FDA in 2022 as not a dietary supplement, though sales continue with regulatory ambiguity.

The biology in one paragraph

Both NMN and NR are precursors that the body converts into NAD+, a coenzyme used in energy metabolism, DNA repair (PARP enzymes), and sirtuin function. NAD+ declines with age across essentially every species studied. The hypothesis underlying both supplements is that restoring NAD+ levels in older adults restores some youthful cellular function. The animal evidence is partially supportive on specific markers (mitochondrial function, insulin sensitivity, exercise capacity) and mixed on whole-organism lifespan. The human evidence is at an earlier stage for both compounds, and the question of whether NMN or NR is metabolically advantageous before reaching cells is unresolved.

What 2020-2025 human trials actually compare

There are no large head-to-head NMN-versus-NR trials with clinical endpoints. Most published trials use one compound versus placebo, at varying doses, in varying populations, for 4 to 24 weeks. What the literature lets you compare is indirect: separate trial pools, each with its own dose range, biomarker panel, and population.

NMN

• Yoshino et al. 2021 (Washington University / Keio University collaboration): 25 postmenopausal women with prediabetes, 250 mg/day for 10 weeks. Improved muscle insulin sensitivity. Small trial, single endpoint, single population.
• Igarashi et al. 2022 (Keio): older adults at 250 mg/day; modest changes in walking speed and grip strength relative to placebo.
• Liao et al. 2023: 80 middle-aged adults at 300, 600, and 900 mg/day for 60 days. NAD+ rose dose-dependently; subjective wellness measures improved; objective performance changes were small.
• Multiple 2024-2025 Japanese and Chinese trials in adults aged 40-80, doses 250-1000 mg/day, durations 4-24 weeks. Findings are broadly consistent: NAD+ rises, subjective wellness measures tend to improve, hard biomarker changes are modest and inconsistent across studies.

NR

• ChromaDex-sponsored trials at 100-1000 mg/day have established that NR raises blood NAD+ across dose ranges, with the curve flattening above roughly 500 mg/day.
• Trials in healthy older adults at 500 mg twice daily for 6-12 weeks show modest blood pressure reduction (a few mmHg in some studies, null in others) and limited effects on cardiovascular biomarkers.
• A small body of trials in Parkinson’s, heart failure, and ataxia populations has shown engagement of the NAD+ pathway and tolerable safety, with clinical outcome signals that remain preliminary.

What this means in practice: if you are choosing between NMN and NR on evidence quality alone, the trial pools are similar in size and similar in maturity. Neither has a clinical outcome result that would justify a strong claim of disease modification.

Dose: how much, and is more better?

The dose-response data on NAD+ raising flattens above roughly 500 mg/day for both compounds. This matters because much of the marketing implies that higher doses produce proportionally better outcomes.

Variable	NMN	NR
Common dose in trials	250-1000 mg/day	250-500 mg/day, sometimes 1000 mg/day
Typical consumer dose	500-1000 mg/day	300-600 mg/day
Above-curve dosing	Above ~600 mg adds little incremental NAD+ raise	Above ~500 mg adds little incremental NAD+ raise
Split dosing	Limited comparative data; sometimes recommended on bioavailability grounds	Trials often used twice-daily dosing

For someone deciding their own dose: the evidence supports starting at 250-500 mg/day of either compound. Going higher than 500-600 mg/day is a marketing-driven choice rather than a trial-supported one.

Cost: 2026 pricing reality

NMN and NR retail prices have converged over the past three years. A useful comparison:

Tier	NMN price per month (500 mg/day)	NR price per month (500 mg/day)
Budget	$25-45 (often dubious purity)	$45-65 (Tru Niagen budget bundles)
Mid-range	$50-90	$70-100
Premium	$100-180	$100-160
Japanese pharma-scale brands (NMN)	$80-200	n/a

Two practical points. First, the floor below which purity becomes suspect is roughly $25-30/month for either compound; below that, certificates of analysis frequently do not match label claims. Second, the gap between mid-range and premium tiers reflects marketing and brand positioning more than ingredient quality.

For US buyers: Renue By Science and ProHealth Longevity sit in the mid-to-premium NMN range with third-party testing. iHerb carries both NMN and NR at mid-range pricing. ChromaDex’s Tru Niagen is the canonical NR brand and is sold directly and through major retailers.

Safety: side effects, interactions, what is and is not known

At studied doses over trial durations of 4-24 weeks, both NMN and NR have shown clean tolerability profiles relative to placebo. Reported adverse events have been mild and broadly comparable across the two compounds: occasional digestive upset, mild flushing, occasional sleep disturbance at higher doses, and headache.

What the trial data does not yet establish:

• Long-term safety beyond 24 months for either compound, including any interaction with cancer biology (NAD+ is involved in cellular processes that are dual-edged with respect to cancer; this is mechanism speculation, not trial evidence either way).
• Safety in pregnancy, lactation, pediatric populations, or in adults with active cancer.
• Long-term interaction profiles with chemotherapy, immunosuppressants, or anticoagulants.

For adults on prescription medication or with a serious medical history, the relevant question is not “is this supplement safe in general” but “is it safe with what I am already taking”, and that conversation belongs with a clinician who has your full chart.

Regulatory: FDA, Japan, EU

The regulatory landscape is the sharpest contrast between the two compounds.

• NR in the US: ChromaDex submitted a New Dietary Ingredient notification that the FDA accepted, giving NR clear dietary-supplement status. Sold without regulatory ambiguity.
• NMN in the US: In late 2022, the FDA stated that NMN cannot be marketed as a dietary supplement because it had been studied as an investigational new drug prior to substantial supplement marketing. Sales have continued at scale, but the formal status is contested and could affect retailer policies.
• NMN in Japan: Treated as a food (functional food framework), with a mature consumer market and pharmaceutical-scale producers including Mitsubishi and Shinkoso. Japanese per-capita consumption is substantially higher than US.
• EU: Both compounds sit in an evolving Novel Food review framework; member-state availability varies.

For a US consumer who values regulatory clarity, NR is the cleaner choice. For a consumer prioritizing Japanese pharmaceutical-grade manufacturing and a broader brand selection, NMN is the larger market.

Brand selection

For NMN, the brands with consistent third-party testing and established research-relationship credibility include Renue By Science, ProHealth Longevity, and the major Japanese producers (Mitsubishi NMN, Shinkoso NMN) sold through Japanese retailers that ship internationally. Premium pricing in this category often reflects packaging and marketing rather than meaningfully higher ingredient quality.

For NR, the market is more concentrated. ChromaDex’s Tru Niagen is the canonical brand and carries the bulk of the published clinical-trial evidence. Several other brands license NR from ChromaDex or use independent supply; certificates of analysis matter here just as much as with NMN.

In both categories, the practical purchase test is: does the seller publish a current certificate of analysis matching label claims, and is the brand priced in the mid-range rather than the suspicious-bargain or marketing-bloat extremes?

Where the evidence still falls short

The honest summary of NMN-versus-NR human evidence in 2026:

• Both compounds raise blood NAD+ at studied doses. This is established.
• Both have shown small-effect improvements on isolated biomarkers in specific populations. The findings are not consistently replicated across trials.
• Neither has produced a clinical outcome result that would justify claims of disease prevention or treatment.
• Long-term human safety data beyond two years is preliminary for both.
• Head-to-head NMN-versus-NR trials with clinical endpoints, in matched populations, at matched doses, do not yet exist in the published literature.

Anyone making a confident NMN-is-better or NR-is-better recommendation in 2026 is going beyond the trial evidence.

Practical decision framework

If you have already optimized exercise, sleep, diet quality, and stress management, and you want to take a calibrated bet on the NAD+ thesis, a reasonable approach is:

• Pick one compound rather than stacking both. The marginal benefit of combining is speculative and the cost doubles.
• Dose at 250-500 mg/day. Do not chase the higher end of the trial range unless future evidence supports it.
• Choose a brand with a current certificate of analysis. Mid-range pricing.
• Plan a 6-month trial with one or two simple personal markers (resting heart rate, subjective energy, recovery from training). Drop the supplement if you do not perceive value at 6 months.
• Revisit annually. The evidence base is moving; what is preliminary in 2026 may be clearer by 2028.

If exercise, sleep, diet, and stress are not yet addressed, neither NMN nor NR is a useful place to spend attention or money. The effect sizes attributed to either supplement are smaller, less certain, and more expensive than the effect sizes available from established health practices.

Verdict

NMN and NR are the most evidence-supported NAD+ precursor supplements as of 2026, but “most evidence-supported” still means “preliminary human data with no clinical outcome confirmation.” Costs have converged. Safety profiles look comparable at trial doses. The dose-response curves both flatten around 500 mg/day. The cleanest distinguisher is US regulatory status, where NR has the cleaner dietary-supplement standing.

For an evidence-conscious consumer, either compound is a defensible calibrated bet at moderate dose, with the understanding that you are betting on the NAD+ thesis itself, not on a confirmed clinical result. For an evidence-skeptical consumer, the answer is the same as for most emerging longevity supplements: wait for the next round of mid-sized clinical-endpoint trials, due 2026-2028.

---

Part of our supplement reviews series. See also: NMN supplements and Japan: hype vs evidence, 5 Japanese longevity habits backed by research.